Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1831 to 1845 of 7707 results

  1. Third molars (impacted) - prophylactic removal [ID898]

    In development [GID-TAG525] Expected publication date: TBC

  2. Nipocalimab for treating generalised myasthenia gravis TS ID 11958

    Awaiting development [GID-TA11492] Expected publication date: TBC

  3. Opicapone for adjunctive treatment of motor signs and symptoms in Parkinson's disease TS ID 11941

    Awaiting development [GID-TA11481] Expected publication date: TBC

  4. Pembrolizumab with chemotherapy then olaparib maintenance for treating BRCA-negative advanced epithelial ovarian, fallopian tube or peritoneal cancer [ID3853]

    Awaiting development [GID-TA10747] Expected publication date: TBC

  5. Bipolar disorder: assessment and management (extraordinary review)

    In development [GID-NG10380] Expected publication date: TBC

  6. Pembrolizumab–vibostolimab for untreated metastatic non-small-cell lung cancer [ID6365]

    Awaiting development [GID-TA11442] Expected publication date: TBC

  7. Tezepelumab for treating severe chronic rhinosinusitis with nasal polyps TS ID 11918

    Awaiting development [GID-TA11429] Expected publication date: TBC

  8. 10395 - Aprocitentan for treating resistant hypertension TS ID 10395

    Awaiting development [GID-TA11459] Expected publication date: TBC

  9. Xeomin (botulinum neurotoxin type A) for treating lower limb spasticity TS ID 11902

    Awaiting development [GID-TA11417] Expected publication date: TBC

  10. Isatuximab in combination as induction therapy for untreated multiple myeloma when an autologous stem cell transplant is suitable TS ID 11949

    Awaiting development [GID-TA11465] Expected publication date: TBC

  11. Pembrolizumab with chemoradiation for untreated muscle-invasive non-metastatic bladder cancer TS ID 11953

    Awaiting development [GID-TA11469] Expected publication date: TBC

  12. Apremilast for treating moderate to severe plaque psoriasis in people aged 6 to 17 TS ID 11921

      Status ...

  13. Teclistamab with daratumumab for treating relapsed or refractory multiple myeloma after 1 or more therapies [ID6201]

    Awaiting development [GID-TA11162] Expected publication date: TBC

  14. Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID3894]

    Awaiting development [GID-TA10777] Expected publication date: TBC